UH Harrington-McLaughlin Heart & Vascular Institute
In the News
Women and Heart Disease (video)
Friday, October 23, 2009 (33 reads)
Dr. Barbara Williams, Director, Women's Cardiovascular Center, University Hospitals Harrington-McLaughlin Heart & Vascular Institute, discusses the specific risks women face when it comes to heart disease. More women than men die from it each year because women often present with less "traditional" symptoms. Watch the video to learn more about risks for heart attack and to hear advice from Dr. Williams.
Read More |
|
Harrington and McLaughlin families honored with the Samuel Mather Visionary Award
Monday, October 12, 2009 (39 reads)
The Harrington and McLaughlin families of Hudson were honored by the University Hospitals-affiliated Society of 1866 with the prestigious Samuel Mather Visionary Award. In 2008, the Harrington and McLaughlin families committed $22.6 million to UH to support the development of innovative technologies and clinical advancements for the early diagnosis and prevention of cardiovascular disease, a very personal cause for their family. The award is named after the renowned Cleveland industrialist, philanthropist, and former University Hospitals Board Chairman and benefactor. Named in honor of UH's founding year, the Society of 1866 recognizes those who generously support the hospital through their annual, lifetime and estate giving.
Read More |
|
Why having sex is good for your health
Tuesday, October 06, 2009 (117 reads)
Sex is good for your health. OK, that's a hugely simplistic statement that requires an even bigger caveat, along the lines of "as long as you are a consenting adult in a positive, monogamous, disease-free relationship." If you trust everything you read in magazines and online, it also helps you look younger, cures migraines and prevents some cancers. Really? A lot of those "Sex Is Good for Your Health" lists (including those e-mailed to me by various health-related companies and Web sites) are woefully lacking in scientific data. The authors seem to think that the "studies show…" phrase is science enough. Click to see what University Hospitals Harrington-McLaughlin Heart & Vascular Institute cardiologist Dr. Barbara Williams has to say.
Read More |
|
Clot-dissolving therapy a hot topic among cardiologists as new drugs look to enter the market
Monday, September 28, 2009 (91 reads)
Even as they digest the latest news on what dose of the clot-dissolving drug Plavix is best during angioplasty, cardiologists are looking at the next generation of clot-busters that could replace Plavix. Clot-dissolving therapy was the big buzz among cardiologists at last week's Transcatheter Cardiovascular Therapeutics conference in San Francisco, according to Dr. Daniel I. Simon, Director, University Hospitals Harrington-McLaughlin Heart & Vascular Institute in Cleveland, Ohio. "What is the best dose of Plavix to be used in heart attacks?" Simon asked. "That is the number one question in cardiology."
Read More |
|
|
|
Pioneer in molecular medicine comes to University Hospitals Harrington-McLaughlin Heart & Vascular Institute
Monday, September 21, 2009 (120 reads)
Dr. Jonathon S. Stamler, whose work has been recognized by numerous awards, published more than 250 original articles, reviews and book chapters, and authored more than 100 patents and applications, will become the first director of the Institute for Transformative Molecular Medicine at University Hospitals Harrington-McLaughlin Heart & Vascular Institute and Case Western Reserve University Cardiovascular Center. Dr. Stamler is coming from Duke University and also will be the first holder of the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation. A $1.5-million gift from the Reitman Family Foundation endowed the newly established chair for preeminent physician scientists who…
Read More |
|
At 19, heart transplant recipient Jack Kachmarik is figuring out how to make a difference with his life
Monday, September 21, 2009 (129 reads)
The doctors at University Hospitals have never seen a patient like Jack Kachmarik. He arrived by helicopter the night of Sunday, May 31. It was unusual enough to see a 19-year-old having a major stroke. Soon, his mother Nancy learned the stroke was a symptom of a bigger problem. Jack needed a new heart. Doctors found that Jack's heart was enlarged, a sign of heart failure. It explained the stroke — when the heart doesn't pump hard enough, blood tends to clot. Dr. Arie Blitz, one of the surgeons, flew out of state early August 19 to remove the heart from the donor. Two and a half hours later, Blitz and the heart arrived at University Hospitals Case Medical Center. Jack's chest was already opened. It took surgeons 66 minutes to remove his heart and stitch in the new…
Read More |
|
First patient enrolled in clinical trial to study those with coronary artery disease who take dual anti-platelet therapy
Monday, August 31, 2009 (98 reads)
Cordis Corporation, a leader in the development and manufacture of interventional vascular technology, announced that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER® Sirolimus-eluting Coronary Stent. "There continues to be debate among clinicians as to the optimal duration of dual antiplatelet therapy and the results from CYPRESS will add important information to our understanding of the role of dual antiplatelet therapy in patients who receive a CYPHER® Stent," said Daniel I. Simon, MD, Principal Investigator of both CYPRESS and NEVO III, a non-randomized, single-arm trial evaluating the clinical outcomes of the NEVO™ Sirolimus-eluting Coronary Stent in approximately 1,200 patients in the United States and Canada. Dr. Simon is Director, Harrington-McLaughlin Heart & Vascular Institute at University Hospitals Case Medical Center in Cleveland, Ohio.
Read More |
|